Adaptive Biotechnologies has appointed Lance Baldo to serve as its chief medical officer. Baldo comes to Seattle-based Adaptive from Roche subsidiary Genentech, where he was senior vice president and head of US medical affairs. His experience also includes posts at The Medicines Company (NASDAQ: [[ticker:MDCO]]) and MedAptus. Earlier this year, Adaptive and Genentech launched a partnership focused on developing personalized cancer immunotherapies.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
